{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Cervix+Cancer&page=26",
    "query": {
      "condition": "Uterine Cervix Cancer",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 833,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Cervix+Cancer&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Cervix+Cancer&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T21:26:38.959Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07227168",
      "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma HNSCC",
        "Non-Small Cell Lung Cancer NSCLC",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "STRO-004",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-11-07",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227168"
    },
    {
      "nct_id": "NCT03073525",
      "title": "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Gynecological Cancers",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2017-05-31",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 6,
      "location_summary": "Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03073525"
    },
    {
      "nct_id": "NCT01365156",
      "title": "Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Squamous Cell Carcinoma",
        "Adenosquamous Carcinoma",
        "Adenocarcinoma",
        "Locally Advanced Malignant Neoplasm",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Extraperitoneal laparoscopic lymphadenectomy (EPLND)",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemoradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2011-08",
      "completion_date": "2020-01-24",
      "has_results": true,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365156"
    },
    {
      "nct_id": "NCT00669422",
      "title": "ChemoFx® PRO - A Post-Market Data Collection Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Uterine Neoplasms",
        "Endometrial Cancer",
        "Vaginal Cancer",
        "Vulvar Cancer",
        "Cervical Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Precision Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2756,
      "start_date": "2006-10",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2012-10-05",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669422"
    },
    {
      "nct_id": "NCT00319748",
      "title": "Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "852A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2006-04",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-26",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319748"
    },
    {
      "nct_id": "NCT00339989",
      "title": "Cervical Cancer Early Endpoints and Determinants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Cancer",
        "Cervical Intraepithelial",
        "Neoplasia",
        "CIN"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 3013,
      "start_date": "2003-09-12",
      "completion_date": "2020-03-11",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00339989"
    },
    {
      "nct_id": "NCT06203106",
      "title": "NYSCF Scientific Discovery Biobank",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ALS",
        "Amyotrophic Lateral Sclerosis",
        "Alzheimer Disease",
        "Alzheimer Disease, Early Onset",
        "Alzheimer Disease, Late Onset",
        "Batten Disease",
        "Corticobasal Degeneration",
        "Dementia",
        "Frontotemporal Dementia",
        "Huntington Disease",
        "Lewy Body Disease",
        "Multiple Sclerosis",
        "Multiple System Atrophy",
        "Parkinson Disease",
        "Parkinson's Disease and Parkinsonism",
        "Progressive Supranuclear Palsy",
        "INAD",
        "Diabetes",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "Diabetes Mellitus, Type 1",
        "Macular Degeneration",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Uterine Cancer",
        "Vaginal Cancer",
        "Vulvar Cancer",
        "PTSD",
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Biological Sample Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "New York Stem Cell Foundation Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Days and older"
      },
      "enrollment_count": 10000,
      "start_date": "2022-11-10",
      "completion_date": "2045-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06203106"
    },
    {
      "nct_id": "NCT02058550",
      "title": "Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Radiation Toxicity",
        "Vaginal Cancer"
      ],
      "interventions": [
        {
          "name": "survey administration",
          "type": "OTHER"
        },
        {
          "name": "computer-assisted intervention",
          "type": "OTHER"
        },
        {
          "name": "telephone-based intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 72,
      "start_date": "2014-09",
      "completion_date": "2020-10-23",
      "has_results": false,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058550"
    },
    {
      "nct_id": "NCT03277482",
      "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Gynecological Cancer",
        "Metastatic Cervical Cancer",
        "Metastatic Ovarian Cancer",
        "Metastatic Vaginal Cancer",
        "Metastatic Vulvar Cancer",
        "Metastatic Endometrial Cancer",
        "Recurrent Cervical Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Vaginal Cancer",
        "Recurrent Vulvar Cancer",
        "Recurrent Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2018-06-01",
      "completion_date": "2022-07-15",
      "has_results": false,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03277482"
    },
    {
      "nct_id": "NCT04230954",
      "title": "Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Recurrent Cervical Cancer",
        "Metastatic Cervical Cancer",
        "Persistent Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Cabozantinib 40 MG oral once a day",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab 200 mg IV every 3 weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Alabama",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2020-04-16",
      "completion_date": "2022-02-16",
      "has_results": false,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-10-15T21:26:38.959Z",
      "location_count": 1,
      "location_summary": "Mobile, Alabama",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04230954"
    }
  ]
}